Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: Biomarker response and survival improvement

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1185-1192

  Salaun, Pierre Yves ^a   Campion, Loïc ^b   Bournaud, Claire ^c   Faivre Chauvet, Alain ^a   Vuillez, Jean Philippe ^d   Taieb, David ^e   Ansquer, Catherine ^a   Rousseau, Caroline ^a   Borson Chazot, Françoise ^c   Bardet, Stéphane ^f   Oudoux, Aurore ^a   Cariou, Bertrand ^g   Mirallié, Eric ^g   Chang, Chien Hsing ^h   Sharkey, Robert M ⁱ   Goldenberg, David M ^h,i   Chatal, Jean François ^j   Barbet, Jacques ^a,j   Kraeber Bodéré, Françoise ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b ICO Gauducheau Cancer Institute ^*  (France)

^c University Hospital   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e University Hospital   (France)

^f Baclesse Cancer Institute   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h IMMUNOMEDICS INC   (United States)

ⁱ CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^j GIP Arronax   (France)

more..

Author keywords

Bispecific antibody; CEA; Doubling time; Medullary thyroid carcinoma; Radioimmunotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; BISPECIFIC ANTIBODY; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN PENTETIC ACID BISPECIFIC ANTIBODY; DIPENTETATE INDIUM BIVALENT HAPTEN I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CALCITONIN BLOOD LEVEL; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DOUBLING TIME; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; IMMUNOSCINTIGRAPHY; LIVER TOXICITY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIOIMMUNOTHERAPY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM METASTASIS; PENTETIC ACID; RADIOIMMUNOTHERAPY; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84864776718     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101865     Document Type: Article

References (36)

1. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107:2134-2142. (Pubitemid 44665646)
2. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148. (Pubitemid 30127676)
3. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:6077-6084. (Pubitemid 41606528)
4. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-3801.
5. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:2323-2330.
6. Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-772.
7. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30:134-141.
8. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-2666.
9. 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-1842.
10. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med. 1996;37:905-911. (Pubitemid 126447119)
11. DeNardo GL, DeNardo SJ, Balhorn R. Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies? Cancer Biother Radiopharm. 2008;23:383-397.
12. Hosono M, Hosono M, Kraeber-Bodéré F, et al. Biodistribution and dosimetry study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med. 1998;39:1608-1613. (Pubitemid 28459897)
13. Kraeber-Bodéré F, Faivre-Chauvet A, Sai-Maurel C, et al. Comparative toxicity and efficacy of one- and two-step (bispecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999;40:198-204. (Pubitemid 29044192)
14. Kraeber-Bodéré F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-3198s. (Pubitemid 29493915)
15. Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006;47:247-255. (Pubitemid 46780889)
16. Chatal JF, Campion L, Kraeber-Bodéré F, et al French Endocrine Tumor Group. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711. (Pubitemid 46622142)
17. Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590-4597. (Pubitemid 350223431)
18. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773-1782. (Pubitemid 29512308)
19. 177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
20. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285-4292. (Pubitemid 47548569)
21. Goldenberg DM, Rossi EA, Sharkey RM, et al. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med. 2008;49:158-163.
22. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103:6841-6846.
23. 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med. 2010;51:1780-1787.
24. 90Ytrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13: 6696-6702.
25. Solomon B, Rischin D. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer. J Clin Oncol. 2012;30:119-121.
26. Akeno-Stuart N, Croyle M, Knauf JA, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007;67:6956-6964. (Pubitemid 47105543)
27. Barbet J, Peltier P, Bardet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39:1172-1178. (Pubitemid 28326146)
28. 68Ga. J Nucl Med. 2011;52:555-559.
29. 18F radiolabeling for PET. J Nucl Med. 2009;50:991-998.
30. 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-1027.
31. 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688.
32. Machens A, Dralle H. Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer. J Clin Oncol. 2010;28:e534.
33. Oye RK, Shapiro MF. Reporting results from chemotherapy trials: does response make a difference in patient survival? JAMA. 1984;252:2722-2725. (Pubitemid 15200143)
34. Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol. 2005;23:5117-5125. (Pubitemid 46224020)
35. Kraeber-Bodéré F, Saï-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;1:267-274.
36. Salaun PY, Bodet-Milin C, Frampas E, et al. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma. Cancer. 2010;116:1053-1058.